In a recent video update to stockholders, Vaxart’s Founder and Chief Scientific Officer discussed the latest advancements in recombinant vaccine platforms. The update highlighted the company’s plans, objectives, and expectations for business operations, funding, financial performance, and regaining compliance with Nasdaq requirements. While emphasizing forward-looking statements, the update also addressed the potential risks and uncertainties […]